Rhone-Poulenc's Giant Leap
Rhone-Poulenc Rorer's new Gencell division is a radical departure for this conservative French company as well as for the industry. Instead of trying to fit one of series of biotech bets into a large internal research structure, it is creating an organization devoted to in-licensing a broad range of technologically compatible probrams centered around gene therapy and cell therapy.
You may also be interested in...
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.